SG11201509753SA - New polymorphic forms of icotinib phosphate and uses thereof - Google Patents
New polymorphic forms of icotinib phosphate and uses thereofInfo
- Publication number
- SG11201509753SA SG11201509753SA SG11201509753SA SG11201509753SA SG11201509753SA SG 11201509753S A SG11201509753S A SG 11201509753SA SG 11201509753S A SG11201509753S A SG 11201509753SA SG 11201509753S A SG11201509753S A SG 11201509753SA SG 11201509753S A SG11201509753S A SG 11201509753SA
- Authority
- SG
- Singapore
- Prior art keywords
- polymorphic forms
- new polymorphic
- icotinib phosphate
- icotinib
- phosphate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/14—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Metallurgy (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Piezo-Electric Or Mechanical Vibrators, Or Delay Or Filter Circuits (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013077091 | 2013-06-09 | ||
PCT/CN2014/079488 WO2014198211A1 (en) | 2013-06-09 | 2014-06-09 | New polymorphic forms of icotinib phosphate and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201509753SA true SG11201509753SA (en) | 2015-12-30 |
Family
ID=52021657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201509753SA SG11201509753SA (en) | 2013-06-09 | 2014-06-09 | New polymorphic forms of icotinib phosphate and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US9688687B2 (es) |
EP (1) | EP3007700B1 (es) |
JP (1) | JP6523259B2 (es) |
KR (1) | KR102270538B1 (es) |
AU (1) | AU2014280710B2 (es) |
BR (1) | BR112015030589B1 (es) |
CA (1) | CA2914698C (es) |
ES (1) | ES2638646T3 (es) |
HK (1) | HK1207589A1 (es) |
RU (1) | RU2712169C2 (es) |
SG (1) | SG11201509753SA (es) |
TW (1) | TWI535724B (es) |
WO (1) | WO2014198211A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3007700B1 (en) | 2013-06-09 | 2017-06-28 | Betta Pharmaceuticals Co., Ltd. | New polymorphic forms of icotinib phosphate and uses thereof |
EP4034137A4 (en) * | 2019-09-27 | 2023-09-20 | Duke University | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF PANCREATITIS |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003519698A (ja) | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ,インコーポレイテッド | 多様な固体形態のハイスループットでの形成、同定および分析 |
US7078409B2 (en) | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
CN104530061B (zh) | 2008-07-08 | 2017-05-10 | 贝达药业股份有限公司 | 埃克替尼盐酸盐晶型、药物组合物和用途 |
BR112014010479A2 (pt) * | 2011-10-31 | 2017-04-25 | Betta Pharmaceuticals Co Ltd | composto, método para preparar um composto, método para a preparação de icotinib a partir de um composto e método para a preparação de cloridrato de icotinib a partir de um composto |
CA2914857C (en) | 2013-06-09 | 2017-08-22 | Betta Pharmaceuticals Co., Ltd | Polymorphic forms of icotinib and uses thereof |
EP3007700B1 (en) | 2013-06-09 | 2017-06-28 | Betta Pharmaceuticals Co., Ltd. | New polymorphic forms of icotinib phosphate and uses thereof |
WO2015051763A1 (zh) | 2013-10-11 | 2015-04-16 | 贝达药业股份有限公司 | 一种含埃克替尼的皮肤外用药物组合物及其应用 |
-
2014
- 2014-06-09 EP EP14810815.2A patent/EP3007700B1/en active Active
- 2014-06-09 AU AU2014280710A patent/AU2014280710B2/en active Active
- 2014-06-09 CA CA2914698A patent/CA2914698C/en active Active
- 2014-06-09 ES ES14810815.2T patent/ES2638646T3/es active Active
- 2014-06-09 SG SG11201509753SA patent/SG11201509753SA/en unknown
- 2014-06-09 BR BR112015030589-0A patent/BR112015030589B1/pt active IP Right Grant
- 2014-06-09 JP JP2016517156A patent/JP6523259B2/ja active Active
- 2014-06-09 TW TW103119974A patent/TWI535724B/zh active
- 2014-06-09 RU RU2016100027A patent/RU2712169C2/ru not_active Application Discontinuation
- 2014-06-09 US US14/896,706 patent/US9688687B2/en active Active
- 2014-06-09 KR KR1020167000373A patent/KR102270538B1/ko active IP Right Grant
- 2014-06-09 WO PCT/CN2014/079488 patent/WO2014198211A1/en active Application Filing
-
2015
- 2015-08-28 HK HK15108361.7A patent/HK1207589A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
BR112015030589A2 (pt) | 2017-07-25 |
EP3007700A4 (en) | 2016-08-10 |
KR20160018714A (ko) | 2016-02-17 |
AU2014280710B2 (en) | 2016-12-22 |
EP3007700B1 (en) | 2017-06-28 |
EP3007700A1 (en) | 2016-04-20 |
WO2014198211A1 (en) | 2014-12-18 |
BR112015030589B1 (pt) | 2022-07-05 |
TWI535724B (zh) | 2016-06-01 |
ES2638646T3 (es) | 2017-10-23 |
KR102270538B1 (ko) | 2021-06-29 |
JP2016520625A (ja) | 2016-07-14 |
CA2914698A1 (en) | 2014-12-18 |
AU2014280710A1 (en) | 2016-01-21 |
CA2914698C (en) | 2017-08-22 |
HK1207589A1 (zh) | 2016-02-05 |
US9688687B2 (en) | 2017-06-27 |
BR112015030589A8 (pt) | 2020-01-07 |
US20160145262A1 (en) | 2016-05-26 |
RU2712169C2 (ru) | 2020-01-24 |
JP6523259B2 (ja) | 2019-05-29 |
RU2016100027A (ru) | 2017-07-18 |
TW201512204A (zh) | 2015-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1216380A1 (zh) | 附接裝置以及使用和製造的相關聯的方法 | |
GB2535360B (en) | Methods of preparing polyhemiaminals and polyhexahydrotriazines | |
GB201401248D0 (en) | Method of manufacture | |
EP2964235A4 (en) | ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE | |
HRP20181710T1 (hr) | Uporaba derivata benzimidazol-prolina | |
IL244268A0 (en) | Heterocyclic compounds and methods of use | |
PL3019477T3 (pl) | Związki heterocykliczne i sposoby ich stosowania | |
HK1224307A1 (zh) | 原毒素- 變體及其使用方法 | |
HK1222339A1 (zh) | 金屬-β-內酰胺酶的抑制劑 | |
HK1218388A1 (zh) | 奧那司酮多晶型形式和使用方法 | |
ZA201600927B (en) | Structural assembly and method of assembly thereof | |
SG11201507389RA (en) | Integration of hydro-dechlorination and hydro-regeneration | |
IL240763B (en) | The halopyrazoles as thrombin inhibitors | |
IL241290A0 (en) | Subprevir polymorphs and methods for their production | |
GB201305231D0 (en) | Method of Manufacture | |
HK1207589A1 (zh) | 埃克替尼磷酸鹽的晶型及其用途 | |
HK1207641A1 (en) | Polymorphic forms of icotinib and uses thereof | |
GB2517189B (en) | Footwear and methods of making footwear | |
EP2971066A4 (en) | PROCESS FOR IDENTIFICATION AND USE OF NEMATIC COMPOUNDS | |
ZA201508950B (en) | New polymorphic forms of icotinib phosphate and uses thereof | |
GB201308639D0 (en) | Biomarkers and uses of thereof | |
HK1198422A1 (en) | Novel uses of colossolactones | |
GB201311291D0 (en) | Method of manufacture | |
AU2013902711A0 (en) | Compounds and methods of their use - IV | |
GB201301262D0 (en) | Method of manufacture |